Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Genotype-guided Treatment in DLBCL
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 1100
- Registration Number
- NCT05351346
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Post-Autologous Transplant Maintenance with Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 50
- Registration Number
- NCT05344833
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)
- Conditions
- Interventions
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Xencor, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT05328102
- Locations
- 🇺🇸
Swedish Cancer Center, Seattle, Washington, United States
🇫🇷CHU de Rennes - Hopital de Pontchaillou, Rennes Cedex, France
🇪🇸Hospital Universitario Virgen de las Nieves, Granada, Spain
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 760
- Registration Number
- NCT05317416
- Locations
- 🇪🇸
Hospital Universitario La Paz, Madrid, Madrid, Comunidad DE, Spain
🇺🇸Banner Gateway Medical Center, Gilbert, Arizona, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
- Conditions
- Interventions
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 34
- Registration Number
- NCT05308654
- Locations
- 🇺🇸
Tulane University School of Medicine /ID# 244854, New Orleans, Louisiana, United States
🇺🇸American Oncology Partners of Maryland /ID# 244858, Bethesda, Maryland, United States
🇺🇸Atrium Health Levine Cancer Institute /ID# 243420, Charlotte, North Carolina, United States
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 17
- Registration Number
- NCT05288062
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 394
- Registration Number
- NCT05283720
- Locations
- 🇺🇸
Alliance for Multispecialty Research (AMR) - Kansas City /ID# 242144, Kansas City, Missouri, United States
🇺🇸Northwell Health - Monter Cancer Center /ID# 245435, Lake Success, New York, United States
🇺🇸Icahn School of Medicine at Mount Sinai /ID# 242123, New York, New York, United States
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Hellenic Society of Hematology
- Target Recruit Count
- 36
- Registration Number
- NCT05280275
- Locations
- 🇬🇷
Anticancer Hospital of Thessaloniki "Theageneio", Thessaloniki, Greece
🇬🇷Department of Clinical Therapeutics, School of Medicine, National Kapodistrian University of Athens (NKUA), Athens, Greece
A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL
- Conditions
- Interventions
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Antengene Corporation
- Target Recruit Count
- 84
- Registration Number
- NCT05265975
- Locations
- 🇨🇳
The Second Affiliated Hospital of PLA Army Medical University, Chongqing, Chongqing, China
🇨🇳Wuhan Union Hospital, Wuhan, Hubei, China
🇨🇳The first Affiliated Hospital of China medical University, Shenyang, Liaoning, China
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- TeneoOne Inc.
- Target Recruit Count
- 270
- Registration Number
- NCT05259839
- Locations
- 🇺🇸
University of Massachusetts - Worcester /ID# 243977, Worcester, Massachusetts, United States
🇺🇸University of Texas Southwestern Medical Center /ID# 243273, Dallas, Texas, United States
🇦🇺Fiona Stanley Hospital /ID# 244753, Murdoch, Western Australia, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.